



SAFETY DATA SHEET

Revision date 14-Jun-2025

Version 4

Page 1 / 13

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name Atarax® (Hydroxyzine hydrochloride) tablets

Product Code(s) 191

Trade Name: Atarax (R)

Chemical Family: Mixture

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Pharmaceutical product used for sedative, anxiolytic, Antipruritic.

1.3. Details of the supplier of the safety data sheet

Pfizer Inc
66 Hudson Boulevard East
New York, New York 10001
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

E-mail address pfizer-MSDS@pfizer.com

1.4. Emergency telephone number

Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

GHS - Classification: Regulated according to Regulation (EC) 1272/2008 and/or other applicable regulations.

Reproductive toxicity Category 2 - H361d

OSHA Classification

Hazards not otherwise classified (HNOC)

Not applicable

Hazards classified under paragraph (d)(1)(ii) of 1910.1200

Not applicable

2.2. Label elements



Signal word

Warning

SAFETY DATA SHEET

Product Name Atarax® (Hydroxyzine hydrochloride) tablets
Revision date 14-Jun-2025

Page 2 / 13
Version 4

Hazard statements H361d - Suspected of damaging the unborn child

Precautionary Statements - EU (§28, P201 - Obtain special instructions before use 1272/2008)

P202 - Do not handle until all safety precautions have been read and understood

P280 - Wear protective gloves and protective clothing

P308 + P313 - IF exposed or concerned: Get medical advice/attention

P405 - Store locked up

P501 - Dispose of contents/container in accordance with local, regional, national, and international regulations as applicable

2.3. Other hazards

Other hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

PBT & vPvB

The product does not contain any substance(s) classified as PBT or vPvB.

Endocrine Disruptor Information

This product does not contain any known or suspected endocrine disruptors.

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Substances

Not applicable

3.2 Mixtures

Hazardous

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Starch (CAS #: 9005-25-8)	*	-	232-679-6	Not classified	Not classified	No data available	No data available
Magnesium Stearate (CAS #: 557-04-0)	*	-	209-150-3	Not classified	Not classified	No data available	No data available
Hydroxyzine hydrochloride (CAS #: 2192-20-3)	12.5 - 32.6		218-586-3	Repr.2 (H361d) Acute Tox.4 (H302)	Not classified	No data available	No data available
Alginic acid (CAS #: 9005-32-7)	*		232-680-1	Not classified	Not classified	No data available	No data available

NonHazardous

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)

SAFETY DATA SHEET

Product Name Atarax® (Hydroxyzine hydrochloride) tablets
 Revision date 14-Jun-2025

Page 3 / 13
 Version 4

Calcium phosphate dibasic, anhydrous (CAS #: 7757-93-9)	*		231-826-1	Not classified	Not classified	No data available	No data available
Lactose (CAS #: 63-42-3)	*	-	200-559-2	Not classified	Not classified	No data available	No data available
Polyethylene glycol (CAS #: 25322-68-3)	*		Not Listed	Not classified	Not classified	No data available	No data available

Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate No information available

Chemical name	Oral LD50 mg/kg	Dermal LD50 mg/kg	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Calcium phosphate dibasic, anhydrous 7757-93-9	7940	7940	No data available	No data available	No data available
Lactose 63-42-3	10000	No data available	No data available	No data available	No data available
Magnesium Stearate 557-04-0	> 2000	No data available	>2	No data available	No data available
Polyethylene glycol 25322-68-3	22000	20000	No data available	No data available	No data available
Hydroxyzine hydrochloride 2192-20-3	950	No data available	No data available	No data available	No data available
Alginic acid 9005-32-7	5000	No data available	No data available	No data available	No data available

This product does not contain candidate substances of very high concern at a concentration >=0.1% (Regulation (EC) No. 1907/2006 (REACH), Article 59).

Additional information

* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret. Non-hazardous ingredients provided for completeness.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation

Remove to fresh air. Seek immediate medical attention/advice.

Eye contact

Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.

Skin contact

Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion

Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

SAFETY DATA SHEET

Product Name Atarax® (Hydroxyzine hydrochloride) tablets
Revision date 14-Jun-2025

Page 4 / 13
Version 4

4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and effects For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians None.

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media Dry chemical, CO2 or water spray.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the chemical Fine particles (such as dust and mists) may fuel fires/explosions.

Hazardous combustion products May emit toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, hydrogen chloride and other chlorine-containing compounds.

Explosion data

Sensitivity to mechanical impact No information available.

Sensitivity to static discharge No information available.

5.3. Advice for firefighters

Special protective equipment and precautions for fire-fighters Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

For emergency responders Use personal protection recommended in Section 8.

6.2. Environmental precautions

Environmental precautions Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

Methods for containment Prevent further leakage or spillage if safe to do so.

Methods for cleaning up Contain the source of the spill or leak. Collect spilled material by a method that controls dust generation. Avoid use of a filtered vacuum to clean spills of dry solids. Clean contaminated surface thoroughly.

Prevention of secondary hazards Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

Reference to other sections See section 8 for more information. See section 13 for more information.

SAFETY DATA SHEET

Product Name Atarax® (Hydroxyzine hydrochloride) tablets
Revision date 14-Jun-2025

Page 5 / 13
Version 4

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

General hygiene considerations

Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions

Store as directed by product packaging.

7.3. Specific end use(s)

Specific use(s)

Pharmaceutical drug product.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

Hydroxyzine hydrochloride

Pfizer OEL TWA-8 Hr: 200 µg/m³

Calcium phosphate dibasic, anhydrous

Latvia

TWA: 10 mg/m³;

Russia

MAC: 10 mg/m³

Starch

ACGIH TLV

TWA: 10 mg/m³

Bulgaria

TWA: 10.0 mg/m³; dust, inhalable fraction

Czech Republic

4.0 mg/m³

Ireland

TWA: 10 mg/m³; total inhalable dust

Russia

TWA: 4 mg/m³; respirable dust

Spain

STEL: 30 mg/m³ (calculated); respirable dust

Switzerland

STEL: 12 mg/m³ (calculated);

OSHA PEL

MAC: 10 mg/m³

United Kingdom

TWA-(VLA-ED): 10 mg/m³;

TWA-MAK: 3 mg/m³; respirable dust

TWA: 15 mg/m³ total dust

TWA: 5 mg/m³ respirable fraction

(vacated) TWA: 15 mg/m³ total dust

(vacated) TWA: 5 mg/m³ respirable fraction

TWA: 10 mg/m³; total inhalable

TWA: 4 mg/m³; respirable

STEL: 30 mg/m³; total inhalable

STEL: 12 mg/m³; respirable

Magnesium Stearate

ACGIH TLV

TWA: 10 mg/m³ inhalable particulate matter

TWA: 3 mg/m³ respirable particulate matter

TWA: 10 mg/m³ inhalable particulate matter except stearates of toxic metals

SAFETY DATA SHEET

Product Name Atarax® (Hydroxyzine hydrochloride) tablets
Revision date 14-Jun-2025

Page 6 / 13
Version 4

Ireland	TWA: 3 mg/m ³ respirable particulate matter except stearates of toxic metals
Spain	TWA: 10 mg/m ³ ; STEL: 30 mg/m ³ (calculated;except Lead stearate); TWA-(VLA-ED): 10 mg/m ³ ;
Polyethylene glycol	
Austria	TWA-TMW: 1000 mg/m ³ ; inhalable fraction
Denmark	STEL-KZGW: 4000 mg/m ³ (4 X 15 min); inhalable fraction
Germany DFG	TWA: 1000 mg/m ³ ; STEL: 2000 mg/m ³ ; TWA-MAK: 250 mg/m ³ ; II(2);inhalable fraction
Germany TRGS	Peak: 500 mg/m ³ ; inhalable fraction
Russia	TWA-AGW: 200 mg/m ³ (exposure factor 2); inhalable fraction
Slovakia	MAC: 10 mg/m ³
Switzerland	TWA: 1000 mg/m ³ ; TWA-MAK: 500 mg/m ³ ;

8.2. Exposure controls

Engineering controls

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section. Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes. Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Eye/face protection

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

Hand protection

Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).

Skin and body protection

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).

Respiratory protection

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.).

Thermal hazards

No information available.

Environmental exposure controls

No information available.

SAFETY DATA SHEET

Product Name Atarax® (Hydroxyzine hydrochloride) tablets
Revision date 14-Jun-2025

Page 7 / 13
Version 4

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Appearance	tablet
Physical state	Solid
Color	Red, yellow, orange, green
Odor	Odorless.
Odor threshold	No information available
Property	Values
Melting point / freezing point	No data available
Boiling point or initial boiling point and boiling range	No data available
Flammability (solid, gas)	No data available
Lower and upper explosion limit/flammability limit	
Lower explosion limit	No data available
Upper explosion limit	No data available
Flash point	No data available
Autoignition temperature	No data available
Decomposition temperature	
SADT (°C)	No data available
pH	No data available
pH (as aqueous solution)	No data available
Kinematic viscosity	No data available
Dynamic viscosity	No data available
Solubility	No data available
Vapor pressure	No data available
Density and/or relative density	No data available
Bulk density	No data available
Liquid Density	No data available
Vapor density	No data available
Particle characteristics	
Particle Size	No information available
Particle Size Distribution	No information available

9.2. Other information

Molecular formula	Mixture
Molecular weight	Mixture

9.2.1. Information with regard to physical hazard classes

No information available

9.2.2. Other safety characteristics

No information available

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

Reactivity No information available.

10.2. Chemical stability

Stability Stable under normal conditions.

Explosion data

 Sensitivity to mechanical impact No information available.

 Sensitivity to static discharge No information available.

10.3. Possibility of hazardous reactions

SAFETY DATA SHEET

Product Name Atarax® (Hydroxyzine hydrochloride) tablets
Revision date 14-Jun-2025

Page 8 / 13
Version 4

Possibility of hazardous reactions No information available.

Hazardous polymerization Will not occur.

10.4. Conditions to avoid

Conditions to avoid

10.5. Incompatible materials

Incompatible materials

Fine particles (such as dust and mists) may fuel fires/explosions.

As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

General Information: The information included in this section describes the potential hazards of the individual ingredients

Short term Accidental ingestion may cause effects similar to those seen in clinical use.

Long Term: Animal studies have shown a potential to cause adverse effects on the fetus.

Known Clinical Effects: The most commonly reported adverse effects seen with the use of hydroxyzine include drowsiness, somnolence, headache, weakness, depression, and irritability.

Acute toxicity

Serious eye damage/eye irritation

Skin corrosion/irritation

Respiratory or skin sensitization

STOT - single exposure

STOT - repeated exposure

Reproductive toxicity

Germ cell mutagenicity

Carcinogenicity

Aspiration hazard

Based on available data, the classification criteria are not met.

Based on available data, the classification criteria are not met.

Based on available data, the classification criteria are not met.

Based on available data, the classification criteria are not met.

Based on available data, the classification criteria are not met.

Based on available data, the classification criteria are not met.

Classification is based on mixture calculation methods based on component data.

Based on available data, the classification criteria are not met.

Based on available data, the classification criteria are not met.

Based on available data, the classification criteria are not met.

Acute Toxicity: (Species, Route, End Point, Dose)

Magnesium Stearate

Rat Oral LD50 > 2000 mg/kg

Rat Inhalation LC50 > 2000 mg/m³

Hydroxyzine hydrochloride

Rat Oral LD50 840 mg/kg

Mouse IP LD50 81 mg/kg

Rat IP LD50 160 mg/kg

Mouse IV LD50 137 mg/kg

Rat IV LD50 45 mg/kg

Alginic acid

Rat Oral LD 50 >5 gm/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Calcium phosphate dibasic, anhydrous	= 7940 mg/kg (Rat)	> 7940 mg/kg (Rabbit)	-
Lactose	> 10 g/kg (Rat)	-	-
Magnesium Stearate	> 10000 mg/kg (Rat)	-	-
Polyethylene glycol	= 22 g/kg (Rat)	> 20 g/kg (Rabbit)	-
Hydroxyzine hydrochloride	= 950 mg/kg (Rat)	-	-

SAFETY DATA SHEET

Product Name Atarax® (Hydroxyzine hydrochloride) tablets
Revision date 14-Jun-2025

Page 9 / 13
Version 4

Alginic acid	> 5 g/kg (Rat)	-	-
--------------	------------------	---	---

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Polyethylene glycol

Eye Irritation Rabbit Mild
Skin Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Magnesium Stearate

13 Week(s) Rat Oral 1092 g/kg LOAEL Liver

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Hydroxyzine hydrochloride

Reproductive & Fertility Rat Oral 400 mg/kg LOAEL Developmental toxicity, Reproductive toxicity

Prenatal & Postnatal Development Monkey Oral 5 mg/kg/day LOAEL Fetal mortality

Prenatal & Postnatal Development Rat Oral 60 mg/kg/day LOAEL Developmental toxicity

Teratogenicity Hydroxyzine when administered to the pregnant mouse, rat, and rabbit, induced fetal abnormalities in the rat and mouse at doses substantially above the human therapeutic range. Hydroxyzine has been associated with teratogenesis in beagle puppies. In pregnant monkeys (one per dose group), oral doses of 6, 8, and 12 mg/kg resulted in abortion in all three pregnancies. However, dosing at 5 or 10 mg/kg did not produce abortions, nor were any gross malformations seen in offspring.

Carcinogenicity

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

11.2. Information on other hazards

11.2.1. Endocrine disrupting properties

Endocrine disrupting properties Based on available data, the classification criteria are not met.

11.2.2. Other information

Other adverse effects No information available.

Section 12: ECOLOGICAL INFORMATION

Environmental Overview: The environmental characteristics of this mixture have not been fully evaluated. Releases to the environment should be avoided.

12.1. Toxicity

12.2. Persistence and degradability

Persistence and degradability No information available.

12.3. Bioaccumulative potential

Bioaccumulation No information available.

SAFETY DATA SHEET

Product Name Atarax® (Hydroxyzine hydrochloride) tablets
Revision date 14-Jun-2025

Page 10 / 13
Version 4

12.4. Mobility in soil

Mobility in soil No information available.

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment Based on available data, the classification criteria are not met.

Chemical name	PBT and vPvB assessment
Calcium phosphate dibasic, anhydrous	PBT assessment does not apply
Polyethylene glycol	Not PBT/vPvB

12.6. Endocrine disrupting properties

Endocrine disrupting properties Based on available data, the classification criteria are not met.

12.7. Other adverse effects

Other adverse effects No information available.
PMT or vPvM properties Based on available data, the classification criteria are not met.

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Waste from residues/unused products

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

UN number: Not applicable
UN proper shipping name: Not applicable
Transport hazard class(es): Not applicable
Packing group: Not applicable
Environmental Hazard(s): Not applicable

SAFETY DATA SHEET

Product Name Atarax® (Hydroxyzine hydrochloride) tablets
Revision date 14-Jun-2025

Page 11 / 13
Version 4

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Calcium phosphate dibasic, anhydrous	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-826-1
AICS	Present
Starch	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	232-679-6
AICS	Present
Lactose	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	200-559-2
AICS	Present
Magnesium Stearate	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	209-150-3
AICS	Present
Polyethylene glycol	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	Not Listed
AICS	Present
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 3
	Schedule 2
Hydroxyzine hydrochloride	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	218-586-3
Alginic acid	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	232-680-1
AICS	Present

National regulations

Germany

Chemical Prohibition Ordinance (ChemVerbotsV)

Not applicable

TRGS 905

Not applicable

SAFETY DATA SHEET

Product Name Atarax® (Hydroxyzine hydrochloride) tablets
Revision date 14-Jun-2025

Page 12 / 13
Version 4

Switzerland

Ordinance on the Incentive Tax on Volatile Organic Compounds (OVOC) SR 814.018	Not applicable
Storage of Hazardous Material	Not applicable
WPO (GSchV) SR 814.201; WPA (GSchG) SR 814.20	Not applicable
Major Accidents Ordinance SR 814.012	Not applicable

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work.

Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Persistent Organic Pollutants

Not applicable

Ozone-depleting substances (ODS) Regulation (EU) 2024/590

Not applicable.

Explosives Precursors Marketing and Use (2019/1148)

Not applicable

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory
DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List
EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances
ENCS - Japan Existing and New Chemical Substances
IECSC - China Inventory of Existing Chemical Substances
KECL - Korean Existing Chemicals Inventory
PICCS - Philippines Inventory of Chemicals and Chemical Substances
AICS - Australian Inventory of Chemical Substances
NZIoC - New Zealand Inventory of Chemicals
TCSI - Taiwan Chemical Substance Inventory

15.2. Chemical safety assessment

Chemical Safety Report No information available

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Full text of any hazard and/or precautionary statements referred to under Sections 2-15

H302 - Harmful if swallowed H361d - Suspected of damaging the unborn child

Data Sources:

Safety data sheets for individual ingredients. Pfizer proprietary drug development information.

SAFETY DATA SHEET

Product Name Atarax® (Hydroxyzine hydrochloride) tablets
Revision date 14-Jun-2025

Page 13 / 13
Version 4

Reason for revision Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information.

Revision date 14-Jun-2025

Prepared By Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.